Lifetime prevalence is approximately 0.7%, with 12-month prevalence around 0.3-0.4% across most population studies (McGrath et al., 2008) [VERIFY]. Incidence is roughly 15 per 100,000 person-years and varies more than threefold across geographic regions and migrant populations. The condition accounts for disproportionate disability, with WHO data placing it among the top causes of years lived with disability in young adults. Age of onset typically falls between the late teens and mid-thirties. Men present earlier (modal onset 18-25) and more often with prominent negative symptoms; women have a later modal onset (25-35) and a smaller secondary peak after age 40, generally with better premorbid function and outcome. Onset before age 13 (childhood-onset Schizophrenia) is rare and typically severe. New-onset psychosis after age 60 is uncommon and should prompt aggressive medical workup. Comorbidity is the rule rather than the exception:

• Tobacco use disorder: 60-80% lifetime prevalence, contributing substantially to excess cardiovascular mortality.
• Cannabis use disorder: approximately 25% lifetime prevalence and a robust dose-dependent risk factor for incident psychosis, particularly with high-potency THC and adolescent exposure.
• Alcohol use disorder: 20-30% lifetime prevalence.
• Anxiety and obsessive-compulsive disorders: 15-25%, often underrecognized.
• Major depressive episodes: 25-50% across the illness course; post-psychotic depression is a recognized presentation.
• Suicide: lifetime suicide mortality approximately 5-6%, highest in the first decade of illness and around hospital discharge (Palmer et al., 2005) [VERIFY].

Established risk factors include a first-degree family history (heritability roughly 0.7-0.8), advanced paternal age, obstetric complications (hypoxia, intrauterine infection, preeclampsia), winter and early-spring birth, urban upbringing, migration (particularly second-generation), childhood adversity, and adolescent cannabis use. All-cause standardized mortality is 2-3 times the general population, with a life expectancy gap of approximately 15-20 years driven primarily by cardiovascular disease (Hjorthoj et al., 2017) [VERIFY].

Schizophrenia is best modeled as a neurodevelopmental disorder in which polygenic risk and early environmental insults disturb cortical maturation, with clinical onset emerging in late adolescence as synaptic pruning, myelination, and prefrontal-striatal circuit refinement complete.

Neurotransmitter systems

The dopamine hypothesis remains the dominant framework, refined from a global hyperdopaminergic model to a regional formulation. Excess presynaptic dopamine synthesis and release in the associative (dorsal) striatum, demonstrated on F-DOPA PET, drive positive symptoms; hypodopaminergic tone in the prefrontal cortex contributes to negative and cognitive symptoms (Howes and Kapur, 2009) [VERIFY]. All approved antipsychotics share D2 receptor antagonism or partial agonism, supporting downstream dopaminergic convergence regardless of upstream cause. Glutamatergic dysfunction, particularly NMDA receptor hypofunction on cortical parvalbumin-positive GABAergic interneurons, is supported by the psychotomimetic effects of ketamine and phencyclidine and by reduced cortical GABA and glutamate markers. The serotonergic system, through 5-HT2A receptor antagonism, underlies the activity of clozapine and most second-generation agents. Muscarinic M1/M4 agonism, exemplified by xanomeline-trospium (Cobenfy), represents the first non-dopaminergic mechanism approved for schizophrenia.

Circuits and imaging

Structural MRI shows lateral and third ventricular enlargement, reduced gray matter volume in the prefrontal cortex, hippocampus, and superior temporal gyrus, and progressive volume loss particularly during the first years of illness. Functional imaging demonstrates Default mode network hyperactivity and impaired task-related deactivation, dysconnectivity between dorsolateral prefrontal cortex and hippocampus during working memory, and aberrant salience signaling in the ventral striatum.

Genetics

Heritability is approximately 0.7-0.8 from twin studies. The largest GWAS to date identified more than 270 risk loci, with the strongest signal at the major histocompatibility complex on chromosome 6, implicating complement C4 and synaptic pruning (Trubetskoy et al., 2022) [VERIFY]. Rare copy number variants, including 22q11.2 deletion (velocardiofacial syndrome, conferring 25-fold elevated risk), 1q21.1, 15q13.3, and 16p11.2, carry larger individual effects but account for a small fraction of cases. Polygenic risk scores currently explain less than 10% of liability variance and are not clinically actionable.

Environmental factors

Prenatal infection (notably influenza and toxoplasmosis), maternal malnutrition, obstetric complications, childhood trauma, urban upbringing, and migration each confer modest individual risk. Cannabis use, particularly high-potency products and adolescent initiation, has the strongest evidence base among modifiable exposures, with relative risks of 2-4 in heavy users (Marconi et al., 2016) [VERIFY].

Integrative model

Current synthesis frames schizophrenia as gene-environment interaction producing aberrant salience attribution: dysregulated mesostriatal dopamine signaling causes neutral stimuli to be experienced as personally meaningful, generating delusions and hallucinations as the brain's attempt to make sense of misattributed significance (Kapur, 2003) [VERIFY]. Negative and cognitive symptoms reflect distinct prefrontal and thalamocortical pathology that is poorly responsive to D2 blockade.

DSM-5-TR (American Psychiatric Association, 2022) [VERIFY] requires the following, paraphrased: Criterion A. Two or more of the following, each present for a significant portion of time during a one-month period (or less if successfully treated), with at least one being item 1, 2, or 3: (1) delusions, (2) hallucinations, (3) disorganized speech, (4) grossly disorganized or catatonic behavior, (5) negative symptoms (diminished emotional expression or avolition). Criterion B. Significant decline in functioning across one or more major domains (work, interpersonal, self-care) below the premorbid level; in childhood or adolescent onset, failure to achieve expected developmental level. Criterion C. Continuous signs of disturbance for at least six months, including at least one month of active-phase symptoms meeting Criterion A. The six months may include prodromal or residual periods marked by attenuated positive symptoms or negative symptoms. Criterion D. Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been excluded, either because no major mood episode occurred concurrently with active-phase symptoms, or because mood episodes have been present for only a minority of the active and residual periods. Criterion E. The disturbance is not attributable to substances or another medical condition. Criterion F. If a history of autism spectrum disorder or a childhood communication disorder is present, the additional diagnosis of schizophrenia is made only if prominent delusions or hallucinations, plus the other required symptoms, are present for at least one month.

Specifiers

• Course specifiers (after one year): first episode (currently in acute episode, in partial remission, in full remission); multiple episodes; continuous; unspecified.
• With catatonia: present when the catatonia criteria are met concurrently.
• Severity: rated 0-4 on each of the five Criterion A symptom dimensions using the DSM-5-TR Clinician-Rated Dimensions of Psychosis Symptom Severity scale.

DSM-5 eliminated the classical subtypes (paranoid, disorganized, catatonic, residual, undifferentiated) present in DSM-IV because of poor reliability and limited prognostic value.

ICD-11 differences

ICD-11 requires only one month of symptoms rather than six and dimensional symptom specifiers (positive, negative, depressive, manic, psychomotor, cognitive) replace the deleted subtypes. Functional decline is not a separate criterion. Bouffee delirante and similar transient psychoses are coded under acute and transient psychotic disorder rather than schizophreniform disorder. Clinically, the ICD-11 threshold captures patients who would meet DSM-5-TR Schizophreniform disorder criteria.

The clinical phenotype divides into positive, negative, cognitive, mood, and motor symptom dimensions. Symptom dimensions cluster but do not segregate cleanly across patients, and most individuals exhibit features from multiple dimensions over the illness course.

Positive symptoms

Delusions are fixed false beliefs not amenable to contrary evidence. Persecutory delusions are most common; referential, grandiose, somatic, religious, erotomanic, and bizarre delusions also occur. Bizarre content (impossible by physical or cultural standards, such as thought withdrawal or external thought insertion) is more specific to schizophrenia. Hallucinations are most often auditory, classically third-person voices commenting on the patient or commanding actions; visual, olfactory, gustatory, and somatic hallucinations occur but should prompt evaluation for a medical or substance etiology. Disorganized speech ranges from circumstantial and tangential thinking to loosening of associations, derailment, word salad, and neologisms. Disorganized behavior includes inappropriate affect, deteriorated grooming, and unpredictable agitation; catatonia presents with stupor, mutism, posturing, waxy flexibility, echolalia, or echopraxia.

Negative symptoms

The five canonical negative symptoms are Avolition, Asociality, Anhedonia, Alogia, and blunted affect. Negative symptoms are subdivided into primary (intrinsic to the disorder) and secondary (attributable to depression, antipsychotic side effects such as parkinsonism or sedation, positive symptoms, substance use, or institutionalization). Distinguishing primary from secondary forms is essential because secondary negative symptoms may respond to addressing the underlying cause, whereas primary negative symptoms remain among the most treatment-resistant features of the illness.

Cognitive symptoms

Deficits in working memory, processing speed, attention, executive function, verbal learning, and social cognition are present in the majority of patients, often predate the first psychotic episode, and correlate more strongly with functional outcome than positive symptom severity. Cognitive impairment is typically 1-2 standard deviations below matched controls and is largely refractory to current pharmacotherapy.

Mood symptoms

Depressive episodes occur in 25-50% of patients, including post-psychotic depression after acute episode resolution. Prominent and sustained mood episodes during active psychotic phases should prompt reconsideration of schizoaffective disorder or a primary mood disorder with psychotic features.

Course

A premorbid phase often features subtle cognitive, social, and motor delays detectable in childhood. The prodromal phase, lasting months to years, includes attenuated positive symptoms (suspiciousness, perceptual abnormalities, magical thinking), social withdrawal, decline in role functioning, and depression or anxiety. The first episode usually emerges in late adolescence or early adulthood, often with an acute or subacute presentation. Subsequent course is variable: roughly 20% achieve sustained recovery, the majority follow a relapsing-remitting pattern with progressive functional decline early in the illness that plateaus, and a minority show continuous severe symptoms.

Atypical presentations

Late-onset (after age 45) and very-late-onset (after age 60) schizophrenia present with prominent persecutory and partition delusions (belief that people or substances pass through walls), preserved affect, and lower antipsychotic dose requirements. Childhood-onset schizophrenia (before age 13) is rare, severe, and associated with greater premorbid impairment and structural brain abnormalities. Red flags suggesting a non-primary etiology include first onset after age 40, fluctuating consciousness, focal neurologic signs, prominent visual or olfactory hallucinations, rapid progression, autonomic instability, and resistance to standard antipsychotic doses.

Primary psychiatric differentials

• Schizoaffective disorder: at least one major mood episode (depressive or manic) concurrent with Criterion A symptoms, but with at least two weeks of psychotic symptoms in the absence of mood symptoms over the lifetime of the illness.
• Schizophreniform disorder: same Criterion A symptoms with total duration 1-6 months. Functional decline is not required.
• Brief psychotic disorder: psychotic symptoms lasting less than one month with full return to premorbid function.
• Delusional disorder: one or more delusions for at least one month without prominent hallucinations, disorganization, or negative symptoms; functioning outside the delusional domain is largely preserved.
• Bipolar I or major depressive disorder with psychotic features: psychosis occurs only during mood episodes.
• Schizotypal personality disorder: lifelong pattern of eccentricity, magical thinking, and social discomfort without sustained psychosis.
• Obsessive-compulsive disorder with poor insight: ego-dystonic intrusive thoughts maintained as fears rather than fixed beliefs.
• Post-traumatic stress disorder with dissociative features: trauma-linked re-experiencing, hypervigilance often misread as paranoia.
• Autism spectrum disorder: social communication deficits without delusions or hallucinations.

Substance-induced psychosis

Stimulants (methamphetamine, cocaine), cannabis (especially high-potency), hallucinogens, synthetic cannabinoids, PCP, MDMA, anticholinergics, corticosteroids, and dopamine agonists can each induce psychosis. Distinguishing features include temporal relationship to use, resolution within four weeks of abstinence, and prominent visual or tactile hallucinations. The diagnostic challenge is that primary psychotic disorders frequently emerge in the context of substance use; persistence beyond one month of confirmed abstinence supports a primary disorder.

Medical and neurologic mimics

• Endocrine: thyroid disease (hyper- and hypothyroidism), Cushing syndrome, Addison disease, parathyroid disease.
• Autoimmune: anti-NMDA receptor encephalitis (younger women, orofacial dyskinesias, autonomic instability, seizures), other autoimmune encephalitides (LGI1, CASPR2, GABA-B), systemic lupus erythematosus, Hashimoto encephalopathy.
• Infectious: HIV, neurosyphilis, herpes simplex encephalitis, Lyme disease, prion disease.
• Neurologic: temporal lobe epilepsy, brain tumors (especially frontal and temporal), traumatic brain injury, multiple sclerosis, Huntington disease, Wilson disease, Parkinson disease and dementia with Lewy bodies, frontotemporal dementia, Alzheimer disease.
• Metabolic and nutritional: hepatic encephalopathy, uremia, hypoglycemia, hyponatremia, hypercalcemia, vitamin B12 and folate deficiency, niacin deficiency (pellagra), acute intermittent porphyria.
• Genetic: 22q11.2 deletion syndrome, Wilson disease, mitochondrial disorders, leukodystrophies (especially metachromatic leukodystrophy and adrenoleukodystrophy).

Anti-NMDA receptor encephalitis warrants particular attention because early immunotherapy improves outcome, and the syndrome may initially present with isolated psychiatric symptoms before the development of seizures, dyskinesias, and dysautonomia (Dalmau et al., 2008) [VERIFY].

Interview approach

Establish safety and rapport before probing psychotic content. Inquire about delusional themes (persecutory, referential, grandiose, somatic, religious) using open-ended questions; ask about hallucinations across all sensory modalities and clarify command content. Assess insight, judgment, and treatment attitudes. Collateral history from family, prior treaters, and medical records is essential because patients with active psychosis frequently underreport or actively conceal symptoms.

Mandatory history elements

• Premorbid functioning, developmental history, school and occupational trajectory.
• Symptom onset, prodrome, course, prior episodes, hospitalizations, and treatment response.
• Substance use history including cannabis, stimulants, alcohol, hallucinogens, and synthetic compounds.
• Family psychiatric history including suicide.
• Medical and neurologic history, head injury, seizures, autoimmune disease.
• Suicide and violence risk assessment, command hallucinations, prior attempts.
• Medication history, adherence, side effects, prior responses.
• Social determinants: housing, supports, legal involvement.

Physical and neurologic examination

Document baseline vital signs, weight, BMI, and waist circumference. Examine for movement abnormalities (parkinsonism, dystonia, akathisia, tardive dyskinesia) using a structured tool such as the Abnormal Involuntary Movement Scale (AIMS). Neurologic examination should screen for focal deficits, cranial nerve abnormalities, soft signs, and orofacial dyskinesias. Skin examination may identify track marks, neurocutaneous stigmata, or rashes (lupus, porphyria).

Validated rating scales

• Positive and Negative Syndrome Scale (PANSS): 30-item, gold standard for clinical trials.
• Brief Psychiatric Rating Scale (BPRS): 18-item, briefer alternative.
• Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS).
• Clinical Global Impression-Schizophrenia (CGI-SCH).
• Calgary Depression Scale for Schizophrenia (CDSS): distinguishes depression from negative symptoms and extrapyramidal effects.
• AIMS for tardive dyskinesia surveillance.
• Brief Assessment of Cognition in Schizophrenia (BACS) or MATRICS Consensus Cognitive Battery (MCCB) for cognitive assessment.

Laboratory and imaging workup at first presentation:

• CBC, comprehensive metabolic panel, fasting glucose and lipids, HbA1c.
• TSH, free T4.
• Vitamin B12, folate, vitamin D.
• HIV, RPR or treponemal-specific syphilis testing, hepatitis B and C.
• Urine toxicology and serum alcohol level.
• Pregnancy test in women of reproductive age.
• ECG: baseline QTc before initiating antipsychotics with QT-prolonging potential (ziprasidone, iloperidone, paliperidone, IM haloperidol).
• Prolactin if symptoms suggestive (galactorrhea, amenorrhea, sexual dysfunction) or before initiating prolactin-elevating agents.
• Brain MRI is recommended at first episode and indicated for atypical presentations, late onset, focal neurologic findings, or treatment resistance. CT is acceptable when MRI is unavailable.
• EEG and lumbar puncture if anti-NMDA receptor encephalitis or another encephalitis is suspected; consider serum and CSF autoimmune encephalitis panels.
• Ceruloplasmin and 24-hour urinary copper if Wilson disease is plausible (under age 40 with movement abnormalities or hepatic involvement).
• Genetic testing including chromosomal microarray for childhood-onset cases or features suggesting 22q11.2 deletion (cardiac defects, palatal abnormalities, hypocalcemia, characteristic facies).

What not to order

Routine viral panels, heavy metal screens, autoimmune panels, structural neuroimaging in straightforward presentations of typical-onset schizophrenia, and PET or SPECT imaging are not indicated outside specific clinical suspicion. Genetic polygenic risk scores are not clinically actionable and should not be ordered.

Treatment combines pharmacotherapy (the foundation of acute and maintenance care), psychosocial intervention, and selective neuromodulation. Integrated specialty early intervention services produce superior functional and symptomatic outcomes in first-episode psychosis, as demonstrated in the RAISE-ETP trial (Kane et al., 2016) [VERIFY] and replicated internationally.

Pharmacotherapy

All approved antipsychotics for schizophrenia share dopamine D2 antagonism or partial agonism. Differences among agents lie primarily in side effect profiles rather than efficacy for positive symptoms, with the established exception of clozapine. The CATIE trial demonstrated comparable effectiveness among most second-generation agents and perphenazine, with olanzapine showing modestly superior all-cause discontinuation at the cost of significant metabolic burden (Lieberman et al., 2005) [VERIFY]. Network meta-analysis confirms small efficacy differences among non-clozapine agents and substantial differences in tolerability (Huhn et al., 2019) [VERIFY]. First-episode patients respond at lower doses than chronically ill patients and are more sensitive to extrapyramidal and metabolic adverse effects. Start low, titrate slowly, and use the minimum effective dose. Adequate trial duration is 4-6 weeks at therapeutic dose; meaningful improvement is typically evident within the first 2 weeks. Switch agents if response is inadequate at 4-6 weeks or if intolerable adverse effects emerge. First-line agents (representative dosing for non-elderly adults):

• Risperidone 2-6 mg/day; effective, prolactin elevation, EPS at higher doses.
• Olanzapine 10-20 mg/day; high efficacy, substantial weight gain, dyslipidemia, dysglycemia.
• Aripiprazole 10-30 mg/day; partial D2 agonist, weight-neutral, akathisia common.
• Quetiapine 400-800 mg/day; sedating, lower EPS, weight gain.
• Paliperidone 6-12 mg/day; renally excreted, mild prolactin elevation.
• Lurasidone 40-160 mg/day with food (>=350 kcal); weight-neutral, akathisia.
• Ziprasidone 80-160 mg/day with food (>=500 kcal); weight-neutral, QTc prolongation.
• Cariprazine 1.5-6 mg/day; partial D3-preferring agonist, akathisia, evidence in negative symptoms (Nemeth et al., 2017) [VERIFY].
• Brexpiprazole 2-4 mg/day; partial D2 agonist, akathisia less than aripiprazole.
• Xanomeline-trospium (Cobenfy) 50-125 mg of xanomeline twice daily; M1/M4 muscarinic agonist with peripheral antimuscarinic, novel non-D2 mechanism.

First-generation agents (haloperidol 2-20 mg/day, fluphenazine 5-20 mg/day, perphenazine 16-64 mg/day) remain effective and often less expensive but carry higher rates of EPS and tardive dyskinesia. Long-acting injectable antipsychotics (LAIs) should be considered early, particularly for first-episode patients, given the mortality and rehospitalization benefit observed in registry data (Tiihonen et al., 2017) [VERIFY]. Available LAIs include haloperidol decanoate, fluphenazine decanoate, risperidone microspheres, paliperidone palmitate (monthly, 3-monthly, 6-monthly formulations), aripiprazole monohydrate (Abilify Maintena), aripiprazole lauroxil, and olanzapine pamoate (with post-injection delirium/sedation syndrome risk requiring 3-hour observation).

Treatment-resistant schizophrenia (TRS)

Defined as failure of two adequate trials (>=6 weeks each, therapeutic dose, confirmed adherence) of different antipsychotics. Approximately 30% of patients meet criteria. Clozapine is the only agent with demonstrated superior efficacy in TRS and is the gold-standard treatment (Kane et al., 1988) [VERIFY]. Clozapine reduces suicide risk and all-cause mortality and carries an FDA-approved indication for suicidality reduction in schizophrenia and schizoaffective disorder (InterSePT, Meltzer et al., 2003) [VERIFY]. It remains underused worldwide. Initiation requires baseline ANC >=1500/microL (>=1000/microL in benign ethnic neutropenia), with weekly monitoring for 6 months, biweekly for 6 months, then monthly under the REMS program. Major adverse effects include agranulocytosis (approximately 0.8%), seizures (dose-dependent, >2% at >600 mg/day), myocarditis (highest in first 8 weeks), cardiomyopathy, severe constipation and ileus, sialorrhea, weight gain, dyslipidemia, dysglycemia, orthostasis, and sedation. Therapeutic plasma level is 350-600 ng/mL. Smoking induces CYP1A2; smoking cessation can double clozapine levels. Augmentation strategies for partial clozapine response have weak evidence; options include adding a second antipsychotic (most commonly aripiprazole or amisulpride), ECT, or lamotrigine. Aripiprazole augmentation may attenuate metabolic effects of clozapine.

Adverse effect management

• Acute dystonia: IM diphenhydramine 25-50 mg or IM benztropine 1-2 mg; switch to lower-potency agent.
• Akathisia: dose reduction, switch agent, propranolol 30-90 mg/day, mirtazapine 15 mg, benzodiazepines short-term.
• Parkinsonism: dose reduction, switch agent, anticholinergic (benztropine 1-4 mg/day) avoiding in elderly.
• Tardive dyskinesia: VMAT2 inhibitors valbenazine (40-80 mg/day) or deutetrabenazine (12-48 mg/day) are FDA-approved; reduce or discontinue offending agent if feasible.
• Neuroleptic malignant syndrome: discontinue antipsychotic, supportive care, dantrolene or bromocriptine in severe cases, ECT if persistent.
• Metabolic syndrome: lifestyle counseling, metformin 500-2000 mg/day for antipsychotic-induced weight gain (particularly olanzapine and clozapine), GLP-1 receptor agonists are under active investigation, switch to weight-neutral agent when feasible.
• Hyperprolactinemia: dose reduction, switch to aripiprazole or other prolactin-sparing agent, dopamine agonist only with caution.
• QTc prolongation: avoid combinations of QT-prolonging drugs, monitor with baseline and follow-up ECG, address electrolyte derangements.

Psychotherapy

• Cognitive behavioral therapy for psychosis (CBTp): structured, time-limited, focused on reducing distress from positive symptoms, normalizing experiences, and behavioral experiments. Recommended by NICE and APA practice guidelines as standard adjunct to pharmacotherapy.
• Family psychoeducation and family-based interventions: reduce relapse and rehospitalization, particularly when expressed emotion is high.
• Assertive Community Treatment (ACT): multidisciplinary, low caseload team for high-utilizing patients with severe illness; reduces hospitalizations.
• Supported employment using Individual Placement and Support (IPS) model: superior to traditional vocational rehabilitation in achieving competitive employment.
• Social skills training: improves social and role functioning when sustained.
• Cognitive remediation: computer- and clinician-delivered training shows modest improvement in cognition and functioning, particularly when paired with vocational rehabilitation.
• Coordinated specialty care for first-episode psychosis (RAISE, EASA, OnTrackNY models) integrates the above modalities.

Neuromodulation

• Electroconvulsive therapy (ECT): indicated for catatonia, severe agitation or aggression, prominent affective symptoms, suicidality, and clozapine-resistant or clozapine-intolerant illness. Bilateral or right unilateral electrode placement at 6 times seizure threshold.
• Repetitive transcranial magnetic stimulation (rTMS): low-frequency stimulation of left temporoparietal cortex has modest evidence for treatment-resistant auditory hallucinations; not standard care.
• Transcranial direct current stimulation (tDCS): experimental, evidence insufficient for routine use.
• Deep brain stimulation: investigational only.

Adjunctive

• Treat comorbid depression with SSRIs after stabilization of psychosis; avoid in acute psychotic exacerbation.
• Treat comorbid anxiety; benzodiazepines may be used short-term for agitation but limit chronic use.
• Address tobacco use; varenicline and nicotine replacement therapy are effective and do not worsen psychiatric symptoms in stable patients.
• Cardiometabolic monitoring per APA and consensus guidelines: weight at every visit, BP and waist circumference quarterly, fasting glucose or HbA1c and lipids at baseline, 3 months, then annually.
• Address substance use disorders with integrated dual-diagnosis treatment.
• Vitamin D, B12, and folate replacement when deficient.

Pediatric and adolescent

Childhood-onset schizophrenia (before age 13) is rare and severe. Aripiprazole, olanzapine, quetiapine, paliperidone, and risperidone carry FDA approval in adolescents (ages 13-17), with risperidone and aripiprazole also approved at younger ages for related indications. Adolescents are particularly susceptible to weight gain, sedation, and prolactin elevation; lower starting doses, slower titration, and intensified metabolic monitoring are required. Differential diagnosis must include autism spectrum disorder, intellectual disability, mood disorders with psychosis, dissociative disorders, anti-NMDA receptor encephalitis, and 22q11.2 deletion syndrome.

Geriatric

Late-onset schizophrenia (onset after age 45) and very-late-onset schizophrenia-like psychosis (after age 60) are recognized presentations. Older adults are highly sensitive to anticholinergic, orthostatic, sedating, and extrapyramidal effects. Antipsychotics carry an FDA boxed warning of increased mortality in dementia-related psychosis; this warning applies broadly to elderly patients with psychotic disorders and mandates careful risk-benefit discussion. Use the lowest effective dose, avoid agents with high anticholinergic burden, and monitor for falls, QTc prolongation, and drug-drug interactions.

Perinatal

Risk of relapse rises substantially in the first months postpartum. Untreated psychosis carries significant maternal and fetal risk and generally outweighs medication risk. Olanzapine, quetiapine, risperidone, and haloperidol have the largest reproductive safety datasets; available evidence does not show major teratogenicity for second-generation antipsychotics, though neonatal extrapyramidal symptoms and withdrawal may occur. Clozapine crosses into breast milk and may cause neonatal agranulocytosis; weigh closely. Consult the National Pregnancy Registry for Atypical Antipsychotics and document shared decision-making. Postpartum LAI use may improve adherence during a high-risk period.

Comorbid medical illness

Cardiovascular disease, type 2 diabetes, COPD, hepatitis C, and HIV are over-represented. Use renal dosing for paliperidone (avoid in CrCl <10), hepatic caution with most agents, ECG surveillance with QT-prolonging agents, and prefer aripiprazole or lurasidone in patients with metabolic syndrome. Drug interactions through CYP1A2 (clozapine, olanzapine), CYP2D6 (risperidone, aripiprazole), and CYP3A4 (quetiapine, lurasidone, ziprasidone) require attention with smoking, fluvoxamine, ciprofloxacin, carbamazepine, valproate, ritonavir, and grapefruit juice.

Comorbid substance use

Integrated dual-diagnosis treatment improves outcomes more than parallel or sequential care. Cannabis use predicts poorer adherence, more frequent relapse, and greater rehospitalization. Long-acting injectables and clozapine are particularly useful when adherence is compromised by ongoing substance use. Tobacco cessation reduces medical mortality and increases plasma levels of CYP1A2 substrates, requiring dose adjustment.

Cultural considerations

Symptom presentation, idioms of distress, family structure, and treatment expectations vary across cultures and shape both diagnostic decisions and treatment engagement. Schizophrenia is overdiagnosed in Black Americans relative to bipolar disorder, often attributable to clinician bias and miscoding of mood-congruent psychosis (Schwartz and Blankenship, 2014) [VERIFY]. Use the DSM-5-TR Cultural Formulation Interview when cultural factors meaningfully shape presentation.

Outcome heterogeneity is the rule. Approximately 20% of patients achieve sustained symptomatic and functional recovery, the majority experience a relapsing-remitting course with residual symptoms and modest to moderate disability, and a minority experience persistent severe illness. Functional outcome correlates more strongly with cognitive performance and negative symptoms than with positive symptom severity. Predictors of better prognosis include female sex, later onset, acute rather than insidious onset, prominent affective symptoms, good premorbid functioning, brief duration of untreated psychosis, absence of substance use, intact social support, and early adherent antipsychotic treatment. Predictors of worse prognosis include male sex, early onset, insidious onset, prominent negative and cognitive symptoms, prolonged duration of untreated psychosis, comorbid cannabis or stimulant use, poor premorbid function, and nonadherence.

Response and remission

First-episode patients show the highest response rates: roughly 70-80% achieve substantial symptom reduction with the first or second antipsychotic trial. Response rates decline with subsequent episodes. Approximately 30% of patients meet criteria for treatment resistance over the illness course; clozapine produces meaningful response in 30-60% of TRS patients.

Relapse

Without maintenance antipsychotic treatment, relapse rates approach 80% within one year of a first episode and exceed 90% within two years; with continued treatment, one-year relapse falls to 20-30% (Leucht et al., 2012) [VERIFY]. Each relapse is associated with longer time to remission and may contribute to progressive functional decline early in the illness. Maintenance treatment is recommended for at least 1-2 years after a first episode and indefinitely after multiple episodes, though shared decision-making about long-term treatment is appropriate in stable patients.

Suicide

Lifetime suicide mortality is approximately 5-6%, with the highest risk in the early years of illness, particularly around the first hospitalization, hospital discharge, and during depressive episodes. Risk markers include male sex, younger age, higher premorbid IQ, depressive symptoms, hopelessness, prior attempts, recent loss, command hallucinations to harm self, and comorbid substance use. Clozapine reduces suicidal behavior and is FDA-approved for that indication.

Mortality

All-cause standardized mortality ratio is 2-3 times the general population, producing a life expectancy gap of approximately 15-20 years. Cardiovascular disease accounts for the majority of excess mortality, driven by smoking, sedentary lifestyle, dietary patterns, antipsychotic-induced metabolic effects, and underrecognition and undertreatment of cardiometabolic disease. Suicide and unintentional injury contribute substantially in the early illness years.

Functional outcome

Employment rates are typically 10-20% in chronic illness, despite expressed desire to work in the majority of patients. Independent living, marriage, and parenthood are achieved by minorities of patients. Cognitive remediation paired with supported employment shows the most consistent functional benefit.

Hospitalization criteria

• Acute danger to self or others, including command hallucinations and severe persecutory delusions with violent ideation.
• Inability to care for self because of severe disorganization, catatonia, or grave disability.
• First-episode psychosis when stabilization, diagnostic clarification, and treatment initiation cannot be safely accomplished outpatient.
• Suspected medical or neurologic mimic requiring inpatient workup.
• Severe medication-induced complications: NMS, severe agranulocytosis, cardiotoxicity.
• Failure of intensive outpatient treatment with worsening function or risk.

Suicide risk markers

Recent hospital discharge, depressive episode, hopelessness, command hallucinations to harm self, prior attempts, recent significant loss, comorbid substance use, akathisia, and emerging insight into illness severity. Inquire directly about active suicidal ideation, plan, intent, access to means, and command content.

Agitation management

• Verbal de-escalation and environmental modification first when feasible.
• Oral medication preferred over IM when accepted: olanzapine 5-10 mg, risperidone 2 mg, or haloperidol 5 mg with lorazepam 2 mg, plus diphenhydramine or benztropine if first-generation agent.
• IM options: olanzapine 10 mg (avoid IM benzodiazepine within 1 hour due to hypotension and respiratory depression risk), ziprasidone 10-20 mg, haloperidol 5-10 mg with lorazepam 2 mg.
• Inhaled loxapine 10 mg is FDA-approved for acute agitation in schizophrenia or bipolar disorder; bronchospasm risk requires available short-acting beta-agonist and excludes patients with airway disease.
• Restraint and seclusion as last resort, time-limited, with continuous monitoring.

Catatonia

Lorazepam challenge (1-2 mg IV or IM) is both diagnostic and therapeutic; titrate to 8-24 mg/day or higher. ECT is highly effective and indicated for malignant catatonia, lethal catatonia, or lorazepam-refractory catatonia. Continue antipsychotics with caution; first-generation agents and dopamine blockade can precipitate or worsen malignant catatonia and NMS in this population.

Neuroleptic malignant syndrome

Tetrad of fever, rigidity, autonomic instability, and altered mental status, with elevated CK, leukocytosis, and elevated transaminases. Discontinue antipsychotic, provide aggressive supportive care including cooling and IV hydration, treat rhabdomyolysis. Severe cases require dantrolene, bromocriptine, or amantadine; benzodiazepines may help if catatonic features predominate. ECT for refractory or recurrent cases. Reintroduction of antipsychotics, when necessary, should occur after at least 2 weeks of resolution with a structurally different lower-potency agent at low dose.

Clozapine-specific emergencies

• Agranulocytosis (ANC <500/microL): immediate discontinuation, hematology consultation, reverse isolation, broad-spectrum antibiotics if febrile, G-CSF if indicated. Permanent discontinuation typically required.
• Myocarditis: highest risk weeks 2-4 of treatment; new tachycardia, fever, chest pain, dyspnea, or troponin or CRP elevation requires urgent evaluation, ECG, echocardiogram, and clozapine hold.
• Severe constipation and ileus: clozapine-associated gastrointestinal hypomotility can be fatal; aggressive prophylaxis with osmotic laxatives, low threshold for imaging if obstipation or abdominal distention.
• Seizures: dose-dependent; valproate is the preferred adjunct, avoiding additional sedation.

Violence risk

Most patients with schizophrenia are not violent and are far more often victims than perpetrators. Identifiable risk factors include comorbid substance use, persecutory delusions targeted at identifiable individuals, command hallucinations to harm others, prior violence, male sex, younger age, nonadherence, and active substance intoxication. Clozapine reduces aggression.

• Lifetime prevalence is approximately 0.7%; heritability is 0.7-0.8.
• Earlier onset and worse premorbid function in men; later onset and a secondary peak after 40 in women.
• DSM-5-TR requires two of five Criterion A symptoms with at least one being delusions, hallucinations, or disorganized speech, plus 6 months of total disturbance.
• ICD-11 requires only 1 month of symptoms and uses dimensional specifiers; subtypes were eliminated in DSM-5.
• The dopamine hypothesis is now regional: hyperdopaminergia in the associative striatum drives positive symptoms; hypodopaminergia in prefrontal cortex contributes to negative and cognitive symptoms.
• Functional outcome correlates more strongly with cognitive deficits and negative symptoms than with positive symptoms.
• 22q11.2 deletion syndrome confers approximately 25-fold elevated risk; consider in early-onset cases with cardiac defects, palatal abnormalities, or hypocalcemia.
• Adolescent cannabis use, particularly high-potency, is the strongest modifiable risk factor with 2-4 fold relative risk.
• All approved antipsychotics for schizophrenia work through D2 antagonism or partial agonism, except xanomeline-trospium (M1/M4 muscarinic agonism).
• Clozapine is the only antipsychotic with superior efficacy in treatment-resistant schizophrenia and is FDA-approved to reduce suicidality.
• Clozapine monitoring: weekly ANC for 6 months, biweekly for 6 months, then monthly; plasma level 350-600 ng/mL.
• VMAT2 inhibitors (valbenazine, deutetrabenazine) are FDA-approved for tardive dyskinesia.
• Long-acting injectables reduce rehospitalization and mortality in registry data and should be offered early.
• Lifetime suicide mortality is approximately 5-6%; highest risk early in illness and post-discharge.
• Life expectancy is reduced by 15-20 years, predominantly from cardiovascular disease.
• First-line agents for first-episode patients should be started at lower doses than for chronic illness because of greater sensitivity to extrapyramidal and metabolic effects.
• Anti-NMDA receptor encephalitis can present as isolated psychosis before seizures and dyskinesias appear; consider in young women with rapid onset, autonomic instability, or refractory symptoms.